# Novo says CagriSema shows greater weight loss than Lilly rival in diabetes patients

> **Newsylist Open Intelligence Dossier** · First detected: 2026-09-21 19:29 UTC · Category: Business · Sources: 7 · Current Velocity: 4.63

## Key People, Organizations & Locations
Lilly, Novo, CagriSema

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| endpoints.news | Novo offers low-dose CagriSema data as approval decision looms | 2026-09-21 13:22 | [Source Link](https://news.google.com/rss/articles/CBMijwFBVV95cUxPTkpsR0pJRWNWNTQzNGNYaGtXTnYtNWNSakxSZ242MlRZSXVVTmlKTURtNDVtOWVYX2tQczVBY0pGaEFiLWliRFJVQ2Zva0tyUkpTUE50VjJvT3JDV3FpZURQbEx3dDZhV2JQb3RVeDhidjJucTBEZXF5cFA5elZFWWtYNGFOMTFBenNzX3RZdw?oc=5) |
| Yahoo Finance | Lilly Gains as Novo Wins a Lower-Dose Weight-Loss Round | 2026-09-21 13:22 | [Source Link](https://news.google.com/rss/articles/CBMikgFBVV95cUxPYlFUTFFSQW1NMVVGVHZtdmhMcS03aXBSOXV4eTRtWVBzemVkNW5vdE80VnIxR09iNGFmS1llVmFvWUYxcWZhV0daNzJ3T1RPa1BrVGdNZ1FyelZ5YzZlbnBIZS04MmExcC0zWEt4blFrSnFqcjh3VnFnN29SdEtSNmlFU21ibWRFQXNaZHRBQUJadw?oc=5) |
| Newsquawk | Novo Nordisk (NOVOB DC) announces topline results from the phase 3 REIMAGINE 5 and REDEFINE 9 trials of once-weekly CagriSema, with CagriSema proving superior to tirzepatide and weight loss of 21% | 2026-09-21 13:22 | [Source Link](https://news.google.com/rss/articles/CBMirwJBVV95cUxPSXNNaWU1eUpFbldEcG5CQm1fTWlGejZEc3VHWWJteFlQYjVsMThvbnlmRXA3RDdnX3pyaGxlc0NidHVRRVpZMGxfUUVxSnMySjBYd05oZzctNkVsN2Q4VkQ2MkRCZFNsa0NYZ09pRGZiR1I5aUhnUlVPLVREUUNVVmxfdXdvRW5IQzBzbGE1bWEtWm8xazlaeDFuc3N4MzNGVDRTS0xXUHE3OGR1NjUtMlpEaThvY1J4LWNhMlMxUTVBckNybG9sdTVqUkRxaGUxMlJEOHNRM1JPTTlYR0JfZGFsTUs4Um1VaGMtbUpDTWVKRTMxV2w4M1JmT3JtOE96R0ZHQ2FtZkdGU3dmNGpnYmlZNGRtSDdTYWk0d0I3LTZ1al9fNG9HdS04MkJXYzA?oc=5) |
| Hilton Head Island Packet | Novo says its next-gen obesity drug tops Lilly rival in late-stage study | 2026-09-21 13:22 | [Source Link](https://news.google.com/rss/articles/CBMiaEFVX3lxTFA5VjZja19PTzYzeUZ5cGdFUGlzY2pXa3JidjFjQUJCVlE0NDVqMWNZdkt4V1B5WldGX2d3bHZ2SUxBYVh3VkdVYkJITGRlQzJUWkc4YUp6Z1JYWjdYcDVDQ25WYUpWQXV6?oc=5) |
| Seeking Alpha | Novo Nordisk says CagriSema bests Eli Lilly's Zepbound (NVO:NYSE) | 2026-09-21 13:22 | [Source Link](https://news.google.com/rss/articles/CBMilAFBVV95cUxNQURBZVc1QUxMN0t4eFp3RWpCUjBGVlc2dWpjRlN2ZzBJbUtxOFFZRkZFRXhFaUM3bUtnRjltWm9mclJPdVJlOFV6d2w4ZFRzM1M3dXhRVVNUQVRzUnlfaFNUY1pTbHFqb1QyeVFmcHJiMHh1UlhKb0tSVG5uMWh1SWdXbmI3X3BtQ2NmRWFTeFAzUEdu?oc=5) |
| PharmaLive | Novo’s CagriSema delivers superior weight loss versus tirzepatide | 2026-09-21 13:22 | [Source Link](https://news.google.com/rss/articles/CBMilwFBVV95cUxNMjNQYURLMllzRVBBRWlYU0JxV1hqWUpMTV91RDJJX19zRk9UbDZUVktUSHBBUlFUQk5xOG9jM2dhQXB6LU1pbGZNT0EyUHY0aWlIbl9rcXVBak9CakdEaHZZV29GWURpY2NlYkNUekpySUY1LVlCQ2lEU1oxa2Y0NkpvRWZUR25mOXlYeUNiMW1DYVJPWXVN?oc=5) |
| reuters.com | Novo says CagriSema shows greater weight loss than Lilly rival in diabetes patients | 2026-09-21 13:22 | [Source Link](https://news.google.com/rss/articles/CBMi2AFBVV95cUxPSHlFWGtzanhmbXJ1bnRkWUREdHp5TVZGT3FxMVBTVFRranIyZUhCWWlHa2dmcUxsLTczakxobmtfaHlaZ2UyZFBidEFubjJ5ZkZzdFVwWkxUMEVUdTBQWFdQYmw3bjVaT0RzQXpHTkRNeHhrcTRRV1Flb2V0T2k4bW5rb2RvdW9FdGhPRUdCZElmVU4zQzJLLWRrV1daUjhXQlNzcGx3eGN3dWNCX09pY3JvUC10T2NzMEZqZHkyc042TWtQQTJQcThmemNxQUFRbG1wV3NqcUs?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-09-21/novo-says-cagrisema-shows-greater-weight-loss-than-lilly-rival-in-diabetes*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*